Visual Stimulation Through Video Therapy to Enhance Lower Limb Motor Recovery After Stroke
Condition(s) studied
Investigational drug(s) / intervention(s)
Active Videotherapy: During active videotherapy sessions, the image inversion program is activated, superimposing movements of the non-paretic limb onto the paretic limb, which is hidden behind the screen. Participants are instructed to imagine and attempt to reproduce the observed movements using their paretic limb. Each participant completes 25 sessions over 5 weeks (5 sessions per week).
Sham videotherapy: During sham videotherapy sessions, participants are seated facing the IVS4 screen without activation of the image inversion program. Participants perform lower limb movements while directly viewing their paretic limb in real time on the screen, corresponding to an action observation condition without visual illusion.
Study summary
This pilot study evaluates video therapy for lower limb motor recovery after stroke, an approach remains insufficiently documented.
This single-center pilot study uses a Single-Case Experimental Design (SCED) to evaluate the effects of intensive video therapy combined with conventional rehabilitation in patients with subacute or chronic post-stroke hemiparesis. Twelve participants will be included and allocated to different baseline durations according to a multiple-baseline SCED design.
The primary outcome is functional mobility, assessed using the Timed Up and Go (TUG) test, measured repeatedly throughout baseline, intervention, and follow-up phases.
Eligibility
Primary outcome measure(s)
- 1. Timed Up and Go Test (TUG) — 5-week
Time required to stand up from a chair, walk 3 meters, return, and sit down (in seconds)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Service de Médecine Physique et réadaptation | Saint-Etienne | France | Recruiting |
More Centre Hospitalier Universitaire de Saint Etienne trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07629674 on ClinicalTrials.gov ↗ ← All trials in France